Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)

September 24, 2026 5:41 AM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $85.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst comments "IONS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found